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Abstract
Objective—To evaluate the use of adjuvant therapy after primary surgery for stage I–III uterine 
carcinosarcoma (CS).
Methods—A multi-institutional retrospective study of women with stage I–III CS was 
conducted. Analyses were stratified by stage (I/II and III). Patients were categorized according to 
adjuvant therapy: observation (OBS), radiation (RT), chemotherapy (CT) or multimodal therapy 
(CT + RT). Overall survival (OS) and progression-free survival (PFS) were analyzed using log-
rank tests and Cox proportional hazards models.
Results—303 patients were identified across four institutions: 195 with stage I/II and 108 with 
stage III disease. In stage I/II disease, 75 (39.9%) received OBS, 33 (17.6%) CT, 37 (19.7%) RT, 
and 43 (22.9%) CT + RT. OBS was associated with a fourfold increased risk of death compared to 
CT (adjusted hazard ratio (aHR) = 4.48, p = 0.003). Patients receiving CT + RT had significantly 
improved PFS compared to those receiving CT alone (aHR = 0.43, p = 0.04), but no difference in 
OS. In the stage III cohort, 16 (15.0%) received OBS, 34 (31.8%) CT, 20 (18.7%) RT, and 37 
(34.6%) CT + RT. OBS was associated with worse OS and PFS compared to CT (OS: aHR = 2.46, 
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p = 0.04; PFS: aHR = 2.39, p = 0.03, respectively). A potential improvement in PFS was seen for 
those treated with CT + RT compared to CT alone, however it was not statistically significant 
(aHR = 0.53, p = 0.09).
Conclusions—Observation after surgery was associated with poor outcomes in uterine CS 
compared to CT and RT alone. Multimodality therapy for women with stage I/II disease was 
associated with improved PFS compared to chemotherapy alone. Novel treatment options are 
needed to improve outcomes in this aggressive disease.
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1. Introduction
In 2015, 54,870 women will be diagnosed with endometrial cancer and 10,170 will die of 
the disease [1]. Uterine carcinosarcoma (CS), previously known as malignant mixed 
mullerian tumor, is an exceedingly rare neoplasm, comprising 2–5% of all uterine tumors, 
with an incidence of fewer than 3 per 100,000 women each year. [2]. The five year survival 
is estimated to be no more than 40%, which confers the worst prognosis of all uterine 
cancers [3]. The most important prognostic factor to be identified to date is tumor stage [4]. 
Due to the aggressive nature of CS, there is a continuing need to identify the best adjuvant 
therapy regimen to improve outcomes.
Uterine CS was initially classified as a uterine sarcoma and termed a malignant mixed 
mullerian tumor. Recently, these tumors have been reclassified as metaplastic carcinomas 
based on in vitro, immunohistochemistry and molecular studies [5–8]. In 2009, the FIGO 
committee introduced a new staging system for uterine sarcomas however; CS remained 
classified for staging purposes with carcinomas of the endometrium due to their biologically 
similar disease pattern [9]. Cell lines established from CS can differentiate into either 
epithelial, mesenchymal components, or both [10]. Clonality studies show derivation of 
these tumors from a monoclonal cancer cell with carcinomatous and sarcomatous 
components of the tumor sharing common genetic alteration [11]. The original classification 
was the rationale for using sarcoma-based chemotherapy.
Several studies have attempted to identify the optimal adjuvant therapy for patients with CS. 
The National Comprehensive Cancer Network (NCCN) recommends adjuvant chemotherapy 
even for patients with early stage disease [12]. The Gynecologic Oncology Group (GOG) 
108 trial compared ifosfamide/cisplatin with ifosfamide alone, while GOG 161 examined the 
combination of ifosfamide/paclitaxel compared to ifosfamide alone [13,14]. The 
combination arms yielded higher response rates and an improved progression free survival 
(PFS); however a survival advantage was only observed with ifosfamide/paclitaxel [14]. 
GOG 150 compared 3 cycles of chemotherapy (cisplatin-ifosfamide-mesna) to whole 
abdominal radiation in stage I–IV CS, and showed no statistical significant difference in 
outcomes. However, the recurrence rate at 5 years was 21% lower (RH = 0.789, 95% CI: 
0.530–1.176), p = 0.245) and the death rate was 29% lower (RH = 0.712,95% CI: 0.484–
1.048, p = 0.085) for those who received chemotherapy [15]. This was beneath the threshold 
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considered clinically important (as determined a priori); however, this study concluded that 
the differences observed favored adjuvant chemotherapy in this population. Many centers 
today are using platinum–taxane combinations in CS as these tumors are now regarded as 
de-differentiated carcinomas of the endometrium rather than sarcomas. The results of GOG 
261 comparing paclitaxel plus carboplatin to ifosfamide plus paclitaxel in patients with stage 
I–IV disease are eagerly awaited [16].
There have been several retrospective reviews examining the effects of post-operative pelvic 
radiation in this population. These studies have shown a consistent decrease in pelvic 
recurrences but no impact on overall survival [17–23]. A 2008 European Organization for 
Research and Treatment of Cancer [EORTC protocol 55,874] trial of sarcoma patients 
included 91 women with early stage CS and showed that pelvic radiation decreased local 
recurrence but did not improve OS [24]. This finding is most likely attributed to the high 
incidence of distant metastasis found when CS recurs, indicating the need for systemic 
therapy.
There have been nonrandomized trials which have suggested a benefit for multimodal 
therapy (chemotherapy combined with radiation) in this population. Einstein et al. (2012) (N 
= 27), found that radiotherapy “sandwiched” between chemotherapy was feasible and had 
favorable outcomes when compared to historic outcomes for women with uterine CS [25]. A 
study of stage III–IV patients with uterine CS reported improved disease free survival with 
multimodal therapy compared to all other groups (observation, radiation alone, 
chemotherapy alone) [26]. To date, no large randomized studies comparing multimodal 
therapy to chemotherapy, radiation, or observation in patients with uterine carcinosarcoma 
has been conducted and further data are needed.
Recommendations from the NCCN for adjuvant therapy include chemotherapy with or 
without radiation and whole abdominal radiation with or without vaginal brachytherapy 
[12]. In this retrospective, multi-institutional observational study, our goal was to assess the 
association between type of adjuvant therapy received and outcomes in women with stage I–
III uterine CS, and specifically to assess outcomes of women treated with multimodality 
therapy vs. either modality alone.
2. Materials and methods
2.1. Study parameters
Institutional Review Board (IRB) approval was obtained by all institutions prior to study 
initiation. A retrospective chart review was conducted of patients diagnosed with stage I–III 
uterine CS between January 1, 1997 and December 31, 2012 at the University of Minnesota, 
University of North Carolina, Duke University and Johns Hopkins University. All patients 
with surgically confirmed stage I–III disease based on the 1988 International Federation of 
Gynecology and Obstetrics (FIGO) staging system for carcinoma of the corpus uteri [27] 
and documented therapy information were included. Patients with stage IV disease were 
excluded from analysis as the majority of these patients received only chemotherapy. 
Clinical data were extracted from inpatient and outpatient charts. Demographic and clinical 
data including age, race, body mass index (BMI), smoking status, parity, cancer and 
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treatment history, date of diagnosis, date of surgery, final pathology results, grade, 
lymphovascular space involvement (LVSI), node positivity, anatomic site positivity 
(presence or absence of residual disease, disease present in cervix, ovaries, uterine serosa or 
vagina), and treatment type were recorded. Patient outcomes included presence and location 
of disease recurrence and death.
2.2. Statistical analysis
Patients were categorized into four groups based on treatment received: observation only 
(OBS), chemotherapy alone (CT), radiation alone (RT), or multimodal therapy (combination 
of chemotherapy and radiation; CT + RT). Temporality of multimodal therapy 
(chemotherapy followed by radiation, radiation followed by chemotherapy, or sandwich 
protocol) could not be examined due to small numbers in each group. Chemotherapy (CT) 
was utilized as the comparison group due to historic data and the use of chemotherapy 
primarily as adjuvant therapy for CS in the past studies. Due to differences in both treatment 
practices and disease outcomes, analyses was stratified by stage (early — I/II and advanced 
— III).
Patient demographic and clinical data were summarized; means ± standard deviations (SD) 
and percentages are presented unless otherwise noted. Comparisons of baseline 
characteristics by treatment received were conducted using Chi-Square tests, Fisher’s Exact 
tests, and linear regression models as appropriate. The presence of and site of recurrence 
during follow-up were compared by treatment using Chi-Square and Fisher’s Exact tests.
PFS was calculated from date of initial treatment to the date of first known progression, 
recurrence or death, or censored at date of last follow-up if disease-free and alive. OS was 
calculated from the date of initial treatment to date of death or censored at the date of last 
follow-up if still alive. OS and PFS were summarized using Kaplan–Meier methods; the 
median time to event for each group is presented when estimable and treatment groups were 
compared using log-rank tests. Additionally, Cox proportional hazards models were 
conducted to include known predictors of OS and PFS and to address possible confounding. 
The effect of treatment type on OS and PFS was calculated after adjusting for variables 
determined prior to the analysis: clinic site, race, cancer history, residual disease, LVSI, 
stage, age at diagnosis, parity, and year at diagnosis. Hazard ratios and 95% confidence 
intervals (CIs) are presented. Data were analyzed using SAS 9.3 (Cary, NC) and p-values 
less than 0.05 were considered statistically significant.
3. Results
A total of 303 patients were identified as meeting the inclusion criteria at the four sites for 
this study; 8 were excluded due to missing treatment information.
3.1. Early stage (I/II) uterine carcinosarcoma
Of them, 195 patients with stage I/II uterine CS were identified; 188 had treatment 
information and were included in the analysis (Table 1). The majority had stage I disease 
(82.5%), the mean age at diagnosis was 67.8 ± 11.1 years, and the mean BMI at surgery of 
32.2 ± 8.4 kg/m2.
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Treatment received included: OBS: 75 (39.9%), CT: 33 (17.6%), RT: 37 (19.7%), and CT + 
RT: 43 (22.9%). There was a statistically significant difference between treatment groups 
with respect to several key characteristics. The mean age of the OBS group was 70.3, and 
was the oldest of the 4 groups (p = 0.07). With respect to race, there was a higher proportion 
of African Americans (60.3%) in the OBS group compared to the CT (28.1%), RT (47.2%), 
and CT + RT groups (39.5%) (p = 0.05). Those with a history of a prior cancer received CT 
(39.4%) more commonly than OBS (18.7%), RT (13.5%), and CT + RT (18.6%) (p = 0.04). 
The majority of patients had stage I disease, though the proportion differed by treatment 
group (93.3% in OBS, 87.9% in CT, 70.3% in RT, and 69.8% in CT + RT; p = 0.001). 
Cervical involvement was different between groups, with those receiving RT (29.7%) and 
CT + RT (28.6%) having the greatest proportion (p = 0.003). The year of diagnosis was 
significantly different between groups, with those receiving OBS and RT being diagnosed 
significantly earlier (p < 0.0001). Parity was also statistically different between groups, with 
the RT group having the highest mean parity (p = 0.02). Of the 37 patients who received 
radiation alone in early stage disease, 62% (22) received WPRT, 25% (9) WPRT/
brachytherapy and 11% (4) brachytherapy alone and 2 patients were missing data. Of the 43 
patients who received CT + RT, 30% (13) had WPRT, 37% (16) had WPRT/brachytherapy 
and 32% (14) received brachytherapy alone. In early stage disease the majority of women 
receiving chemotherapy alone received paclitaxel/carboplatin (54%), the next most common 
regimen was paclitaxel/ifosfamide (27%), followed by ifosfamide/cisplatin (18%). The 
majority (62%) of patients with early stage disease receiving CT + RT had paclitaxel/
carboplatin with cisplatin/ifosfamide being the second most common agents used.
The median follow-up was 31 months (range 1–160). There was no statistical difference in 
the rate of recurrence between treatment groups (Table 1). The majority of recurrences in the 
RT and CT + RT groups occurring outside of the pelvis (63.6% and 50.0%, respectively) 
compared to 31.0% and 13.3% in the OBS and CT alone groups, however this was not 
statistically significantly (p = 0.07).
Graphs of the OS and PFS by treatment group are presented in Fig. 1a and b. In the 
multivariate analysis, there were statistically significant differences in survival outcomes by 
clinical variables, including clinic site, age, disease stage, and residual disease (Table 2). 
Increased disease stage and age were associated with worse PFS and disease stage and 
presence of residual disease was associated with worse OS. Both also showed differences by 
site. After adjustment for potential confounders, OBS was associated with a more than four-
fold increased risk of death compared to CT alone (adjusted hazard ratio (aHR) = 4.48 [95% 
CI: 1.67–12.02], p = 0.003). OBS was associated with a two-fold increased risk of death 
compared to RT alone (aHR = 2.07 [95% CI: 1.01–4.22], p = 0.05). Multimodality therapy 
was associated with improved PFS compared to CT alone (aHR = 0.43 [95% CI: 0.19–0.95], 
p = 0.04), but there was no difference in OS (aHR = 0.94 [95% CI: 0.34–2.65], p = 0.91). 
There was not a statistically significant difference in PFS or OS between RT and CT alone.
3.2. Advanced stage (III) uterine carcinosarcoma
A total of 108 patients with Stage III uterine CS were identified; 107 had treatment 
information and were included in the analysis (Table 3). The majority had stage IIIC disease 
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(63.6%), the mean age at diagnosis was 67.1 ± 10.1 years, most were Caucasian (52.8%), 
mean BMI was 31.5 ± 6.9 kg/m2. Only 16 (15.0%) were in the OBS group; the majority 
received CT: 34 (31.8%), RT: 20 (18.7%), or CT + RT: 37 (34.6%). There were statistically 
significant differences between treatment received and race (p = 0.01), with the majority of 
OBS and RT groups being African American (75.0% and 65.0%) compared to the CT 
(41.2%) and CT + RT (30.6%) groups. The presence of LVSI was statistically different 
between treatment groups, with those in the RT group having the fewest patients with LVSI 
compared to the other groups (p = 0.02). Evidence of residual disease and ovarian 
involvement was statistically significantly different between groups, with the OBS group 
having the highest percentage of patients with residual disease and ovarian disease (p = 0.04 
and 0.02, respectively).
The median follow-up was 19.0 months (range 1–119). There was not a statistical difference 
in recurrence rates between the treatment groups (p = 0.36), however, site of initial 
documented recurrence was significantly different (Table 3; p = 0.001), with the majority of 
those in the CT and RT groups recurring outside of the pelvis (85.7% and 81.8%, 
respectively) while those in the CT + RT group recurred both in the pelvis (31.3%) and 
outside the pelvis (56.3%).
In advanced stage disease, 20 received RT alone and of those 50% (9) received WPRT, 27% 
(5) WPRT and brachytherapy, 11% (2) WAR, 5% (1) brachytherapy alone, and one had 
extended field RT. For stage III patients receiving CT + RT, 43% (16) received WPRT, 43% 
16) WPRT/brachytherapy, 8% (3) brachytherapy alone, and 5% (2) received extended field 
RT. The majority of this group receiving CT or CT + RT received paclitaxel and carboplatin; 
39% and 48%, respectively. This was followed by ifosfamide/paclitaxel (24%) in CT alone 
arm and cisplatin/ifosfamide (21%) in the CT + RT arm.
Graphs of the OS and PFS by treatment group are presented in Fig. 2a and b. There were 
statistically significant differences in PFS and OS by clinic site and disease stage among 
patients with stage III disease (Table 4). The presence of LVSI was also associated with 
worse PFS and OS. After adjusting for potential confounders, OBS was associated with 
lower PFS and OS compared to CT alone (aHR = 2.39 [95% CI: 1.11–5.17], p = 0.03 and 
aHR = 2.46 [95% CI: 1.05–5.79], p = 0.04, respectively). The data suggest a possible 
improvement in PFS for those treated with CT + RT compared to CT alone (aHR = 0.53 
[95% CI: 0.26–1.11], p = 0.09) though this association was not statistically significant. The 
association was similar but also not significant for OS (aHR = 0.58 [95% CI: 0.25–1.33], p = 
0.20). There was not a significant difference in PFS or OS between RT and CT alone (PFS: 
aHR = 0.94 [95% CI: 0.35–2.50], p = 0.90 and OS: aHR = 1.26 [95% CI: 0.45–3.50], p = 
0.66).
4. Discussion
In this retrospective multi institutional study, we found that in patients with early stage CS, 
there was over a four-fold increase in the risk of death in patients who were observed 
compared to those who received adjuvant chemotherapy. There was significantly higher PFS 
in patients with early stage disease in the CT + RT group compared to the CT group. 
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However, this did not translate into a difference in overall survival raising the question if 
toxicity of multi-modal therapy is worth the price if no OS benefit is observed. The 
improvement in PFS could be due to delay in recurrence in those receiving CT + RT. While 
there was a trend toward improved PFS in advanced staged patients receiving multimodal 
therapy, this did not reach statistical significance.
The findings of our study are similar to those of by Cantrell et al. (2012) showing that 
patients with early stage disease who received adjuvant therapy (chemotherapy +/− radiation 
therapy) had improved PFS but not OS when compared to observation alone [28]. However, 
our study did find a 4 fold increased risk of death for those patients who did not receive 
adjuvant therapy compared to those receiving CT, suggesting that there may be benefit to 
adjuvant therapy in those with early stage disease. Of note, in Stage III disease, the OBS 
group did have the highest percentage of women with residual disease and ovarian 
involvement. Logically this would seem the population that most likely would benefit from 
adjuvant therapy. The rationale for observation rather than adjuvant therapy was not 
consistently provided and represents the innate bias that is present in retrospective studies. 
We hypothesize that if these patients had extensive residual disease remaining following 
surgery perhaps adjuvant therapy was not offered as it may have been thought to be futile in 
such aggressive disease. This could have contributed to the poorer outcome seen in the OBS 
group. It is unclear why improvement in PFS was not observed as well in the CT vs OBS 
group; there could be selection bias in the treatment groups, with definite differences, such 
as age and race, present between the groups. Although it is possible that there is a subgroup 
of patients that may not require adjuvant therapy, identifying those patients based on risk 
factors in this study was not feasible. Due to small sample sizes, we were unable to identify 
an early stage subgroup in which observation was associated with equal or better outcomes 
when compared to the adjuvant treatment cohorts. Genomic data may assist in differentiating 
those patients who are less likely to recur and therefore may ultimately not require adjuvant 
therapy. Until such markers are confirmed, however, our study suggests the use of adjuvant 
therapy for early staged uterine CS.
In the multivariate analyses, several factors were associated with poorer outcomes in both 
the early and advanced stage disease groups. In the early stage group, residual disease and 
stage II disease were associated with poorer outcomes, which is consistent with previous 
studies identifying stage as a predictor of outcome in CS [4,28]. In the advanced group, 
LVSI and higher stage were associated with worse outcome. Interestingly, in both groups, 
we observed statistical differences in PFS and OS according to treatment site. This finding is 
supported by a recent SEER database study of early stage elderly CS patients which showed 
a difference between outcomes based on region of the country where patients were treated 
[29]. Other studies have supported different outcomes according to region treated, 
particularly in elderly patients [30]. Our findings may represent additional regional 
differences that exist among the patients treated at differing sites that are associated with OS 
and PFS and cannot be captured using medical records, such as socioeconomic status, 
insurance status, geographic location, and education. There were racial differences 
according to treatment site. We found that 60% of the early staged patients observed 
following surgery were black. It is well known that black women with endometrial cancer 
have a poorer prognosis compared to white women. The factors contributing to this are 
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multifactorial and include later diagnosis, disparities in access and treatment, comorbidities, 
and tumor genetic differences [31,32]. Therefore, we adjusted for race in these analyses, 
however other potential confounders such as socioeconomic status and education of the 
population treated at the different institutions may have contributed to the differences 
observed in survival according to site treated. There may have also been differences between 
sites in follow up practices, physician bias, and data collection.
A particular interest when considering adjuvant therapy for patients with CS is the location 
of recurrence. In the EORTC 2008 trial of sarcoma patients, while pelvic recurrences were 
decreased by pelvic radiation, OS was not affected, which the authors suggested was 
because the recurrences were distant [24]. Secord et al. found that patients with stage IIIC 
endometrial cancer treated with chemotherapy alone were more likely to develop vaginal or 
pelvic recurrences compared to those treated with radiation or combination therapy [33]. 
Several other retrospective studies have also shown an improvement in local recurrence with 
radiotherapy, but these have not translated into improved OS [21,34]. We found that in the 
early stage group, although there were no differences in recurrence rates comparing the 
treatment groups, there was evidence of a difference in site of recurrence. The RT and CT + 
RT groups had a greater number of extra pelvic recurrences, whereas those receiving CT 
alone tended to recur in the pelvis. The results among patients with advanced stage disease 
were similar and statistically significant by site. Though the majority of recurrences in the 
CT and RT alone groups were extra pelvic, those in the CT + RT group recurred equally in 
the pelvis and distantly. We believe this speaks to the aggressiveness of the disease when it 
presents at more advanced stages. Despite a multi-modal approach to the disease, it recurs 
both in field and distantly, again highlighting the need for new therapies in advanced stage 
CS.
There are limitations to this study. As this was a retrospective study, treatment modalities 
were not randomized. Due to the low incidence of disease, data were pooled from four large 
institutions which had different patient populations and treatment practices. Despite pooling 
15 years of data from four institutions, the sample sizes were only moderate for survival 
analyses. In addition, the sample size did not allow for exploration of our secondary 
objective, which was to explore the role of temporality of the adjuvant therapies among 
those who received multimodal therapy. Finally, there is an innate selection bias with 
retrospective studies. In our study population among those with early stage disease who 
were observed, a large percentage was older and African American, which may be an 
explanation for our findings. It is unknown whether biological differences access to care or 
other confounding socioeconomic factors contributed to differences in the treatment 
planning offered to patients.
In this large, multi-center analysis of women with uterine CS, observation was associated 
with worse outcomes. Our data shows that multimodality therapy was associated with 
improved PFS compared to chemotherapy alone in early stage disease. However, given the 
lack of difference in OS in stage I/II disease when comparing CT + RT to CT alone, and 
with no significant survival differences observed in advanced disease comparing CT + RT to 
CT, it appears that systemic relapse is the norm. Although beneficial in preventing local 
relapse, the lack of radiation effect with regard to overall survival is notable. The optimal 
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chemotherapy has yet to be determined. With further understanding that CS is actually an 
endometrial cancer with a de-differentiated component, new classification within clinical 
trials as well as novel therapeutics and treatment approaches should be considered to 
improve outcomes in women with this disease.
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• Multimodal therapy for stage I/II uterine CS shows improved PFS over 
chemotherapy.
• In early stage CS, there is a 4 times greater risk of death without 
adjuvant therapy.
• Novel therapeutics are necessary to improve overall survival in patients 
with CS.
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Progression-free and overall survival for patients with stage I/II uterine carcinosarcoma. 
Kaplan–Meier curves for a) progression-free survival and b) overall survival are presented 
by treatment received. OBS = observation only; CT = chemotherapy alone; RT = radiation 
alone; CT + RT = multimodal therapy.
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Progression-Free and Overall Survival for Patients with Stage III Uterine Carcinosarcoma. 
Kaplan–Meier curves for a) progression-free survival and b) overall survival are presented 
by treatment received. OBS = observation only; CT = chemotherapy alone; RT = radiation 
alone; CT + RT = multimodal therapy.
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Table 2
Multivariate cox proportional hazards model results for progression-free and overall survival for patients with 
stage I/II uterine carcinosarcoma.
Variable
Progression-free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
CT + RT vs. CT 0.43 (0.19–0.95) 0.04 0.94 (0.34–2.65) 0.91
RT vs. CT 0.81 (0.37–1.76) 0.59 2.13 (0.79–5.71) 0.13
OBS vs. CT 1.73 (0.84–3.57) 0.14 4.48 (1.67–12.02) 0.003
Site 4 vs. Site 1 0.41 (0.18–0.91) 0.03 0.28 (0.10–0.77) 0.01
Site 3 vs. Site 1 0.62 (0.36–1.06) 0.08 0.49 (0.26–0.94) 0.03
Site 2 vs. Site 1 0.43 (0.21–0.89) 0.02 0.33 (0.14–0.77) 0.01
Race (White vs. Black/Other) 1.18 (0.71–1.97) 0.53 1.52 (0.82–2.82) 0.19
Cancer history (Yes vs. No) 0.91 (0.51–1.64) 0.76 1.23 (0.62–2.44) 0.55
Residual disease (Yes vs. No) 2.26 (0.49–10.34) 0.30 4.88 (0.97–24.51) 0.05
LVSI (Yes vs. No) 0.80 (0.48–1.35) 0.40 1.29 (0.70–2.36) 0.41
Stage (II vs. I) 3.28 (1.82–5.94) <0.0001 2.86 (1.47–5.59) 0.002
Age (continuous) 1.03 (1.00–1.05) 0.03 1.01 (0.98–1.04) 0.45
Year of diagnosis (continuous) 1.05 (0.99–1.11) 0.13 1.06 (0.99–1.14) 0.11
Parity (continuous) 0.97 (0.87–1.09) 0.59 1.06 (0.99–1.14) 0.40

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dickson et al. Page 22
Table 4
Multivariate Cox proportional hazards model results for progression-free and overall survival for patients with 
stage III uterine carcinosarcoma.
Variable
Progression-free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Multimodal therapy vs. chemotherapy alone 0.58 (0.27–1.25) 0.17 0.51 (0.22–1.16) 0.10
Radiation therapy vs. chemotherapy alone 0.95 (0.36–2.50) 0.91 1.19 (0.42–3.38) 0.74
Observation alone vs. Chemotherapy alone 2.41 (1.16–5.21) 0.03 2.40 (1.03–5.56) 0.04
Site 4 vs. Site 1 6.15 (1.70–22.32) 0.01 4.61 (1.03–20.63) 0.05
Site 3 vs. Site 1 1.61 (0.72–3.59) 0.25 1.52 (0.61–3.79) 0.37
Site 2 vs. Site 1 1.82 (0.67–4.96) 0.24 1.83 (0.91–5.49) 0.28
Race (White vs. Black) 0.66 (0.34–1.28) 0.22 0.56 (0.27–1.19) 0.13
Cancer history (Yes vs. No) 1.31 (0.63–2.70) 0.47 1.75 (0.76–4.07) 0.19
Residual disease (Yes vs. No) 1.72 (0.78–3.80) 0.18 1.69 (0.70–4.08) 0.25
LVSI (Yes vs. No) 2.56 (1.11–5.89) 0.03 3.82 (1.41–10.38) 0.01
Stage IIIC vs. IIIA 2.78 (1.38–5.61) 0.004 2.89 (1.30–6.43) 0.01
Stage IIIB vs. IIIA 0.52 (0.06–4.14) 0.53 0.44 (0.04–4.37) 0.48
Age (continuous) 1.00 (0.97–1.03) 0.98 1.00 (0.96–1.03) 0.95
Year of diagnosis (continuous) 1.02 (0.95–1.10) 0.60 1.04 (0.95–1.13) 0.43
Parity (continuous) 1.02 (0.86–1.21) 0.82 1.00 (0.83–1.21) 0.98
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